Ocuphire Pharma welcomes Susan Benton to its Board as Independent Director

– USA, MI –  Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced the appointment of industry veteran Susan Benton to its Board as Independent Director, effective November 5, 2020.

Separately, Ocuphire has also announced the completion of merger and financing transactions and has commenced trading today as a public company (Nasdaq: OCUP).

“We are truly excited to welcome our new independent board member,” said Board chair, Cam Gallagher. “Susan brings a wealth of knowledge and relationships from her comprehensive experience developing and commercializing ophthalmic therapeutics across global markets. We are looking forward to her contributions.”

About Susan Benton

Susan Benton brings more than 30 years of experience in the life sciences, with over 20 years specifically focused on ophthalmology. She currently serves as the General Manager and Head of the United States for Thea Pharma, Inc., a wholly-owned subsidiary of Thea Laboratories, a leading independent ophthalmic pharmaceutical company based in France. Susan has extensive experience in strategy, commercial operations, and business development. Previously she held leadership roles at Shire, a specialty biopharmaceutical company, where she played an instrumental role in expanding their ophthalmic pipeline. Susan has also held senior leadership positions at Bausch + Lomb, Sirion Therapeutics, and Johnson & Johnson where she helped launch ophthalmic brands including Lotemax, Alrex, Optivar, Durezol, and Zirgan. She has provided strategic consulting services for over a dozen ophthalmic start-up companies and serves on the boards of several emerging biotech companies.

“I am honored to have been selected to join Ocuphire Pharma’s board of directors. The next year will prove to be transformative for Ocuphire, and I am excited to advise the team in navigating their upcoming clinical milestones and pre-commercial activities. I hope to add a unique breadth of experience that will complement the impressive backgrounds of Ocuphire’s current board and management team,” said Susan Benton.

About Ocuphire Pharma

Ocuphire is a publicly-traded, clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting the front and back of the eye indications. The company’s lead product candidate, Nyxol Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances, pharmacologically-induced mydriasis, and presbyopia. Ocuphire’s second product candidate, APX3330, is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late-stage development, regulatory preparation, and commercialization of drugs in key global markets.

For more information: https://www.ocuphire.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team